Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.6452W HIGH $39.00
Volume
1.76 K
Value Traded
42.13 K
Short % Float
6.14%
-3.42%Week
-11.46%1 Month
+15.07%3 Month
+10.75%6 Month
-98.03%5 Year
-98.03%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
42.26 M
EPS (TTM)
-3.32
P/E Ratio
-
Ent. Value
41.18 M
Total Shares
6.51 M
Float Shares
950.00 K
Insiders
85.44%
Institutions
1.65%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TVGN Catalyst Timeline
Dated clinical, regulatory and corporate events for Tevogen Bio Holdings Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tevogen Bio Holdings Inc.
161Total events
2Upcoming
46Tier-1 (high impact)
2023 to 2026Coverage
Upcoming catalysts 2
TBD
T1Partnership / License
Subscribe to view catalyst details
TBD
T3Manufacturing Milestone
Subscribe to view catalyst details
Event history 50
▼Equity OfferingCorporate
Tevogen announces $3 million PIPE financing at $8 per prefunded warrant
◆Partnership / LicenseCorporate
Evaluating potential co-development partnerships for PredicTcell platform
▲Quarterly UpdateCorporate
Tevogen regains compliance with Nasdaq minimum bid price requirement
●Oral PresentationPresentation
Mittul Mehta speaks at Microsoft Fabric Community Conference (FabCon 2026)
▲Platform ValidationPreclinical
PredicTcell Beta recall improved from 87% to 92%, precision from 40% to 48%
◆AcquisitionCorporate
Signed Letter of Intent to evaluate potential acquisition of Apozeal Pharmaceutical
◆Partnership / LicenseCorporate
Tevogen signs non-binding LOI to evaluate potential acquisition of Sciometrix
▲Trial CompletionTrial
Proof-of-concept clinical trial completed for TVGN 489 in high-risk COVID-19 patients
COVID-19source ↗
▲Preclinical PoCPreclinical
Completion of T cell target identification for five additional HLA restrictions
Acute and Long COVIDsource ↗
▲Dose Finding UpdateTrial
Dose-finding clinical trial of TVGN 489 demonstrated favorable safety profile and provided insights for next phase
COVID-19 and Long COVIDsource ↗
▲PublicationPresentation
Dose-finding trial results published in Blood Advances
COVID-19 and Long COVIDsource ↗
◆Oral PresentationPresentation
CIO Mittul Mehta to join Startup Forum panel at Databricks DATA + AI World Tour
▲Platform ValidationPreclinical
PredicTcell Beta data expansion to 100x with 12.4 million records
▲Topline ReadoutClinical Data
TVGN 489 demonstrated promising results in Proof-of-Concept clinical trial
Long COVIDsource ↗
▲Full ResultsTVGN-489Clinical Data
Phase I proof-of-concept results published in Blood Advances showing TVGN-489 enabled stem cell transplant without COVID-19 reactivation
SARS-CoV-2 infection in high-risk vulnerable patients; Long-COVID with persistent viral reservoirsource ↗
▲Quarterly UpdateTVGN-489Corporate
Risk-adjusted net present value (rNPV) estimate of $9–$11 billion for TVGN-489
SARS-CoV-2 infection; Long-COVIDsource ↗
▲Full ResultsClinical Data
Publication of positive POC/dose finding clinical trial data of TVGN 489 in Blood Advances
SARS-CoV-2 infectionsource ↗
◆Quarterly UpdateCorporate
Tevogen to provide detailed information and valuation of internally developed assets in the coming days
▲Patent GrantedIP / Competition
Patent publication of proprietary machine learning technology for predicting immunologically active peptides
▲Patent GrantedIP / Competition
WIPO publishes international patent application for AI technology predicting immunologically active peptides
▲Manufacturing MilestoneCMC / Inspection
Signed letter of intent to lease cell therapy manufacturing facility in New Jersey
▲Platform ValidationPreclinical
Tevogen.AI builds alpha version of PredicTcell model with Microsoft and Databricks
◆Preclinical PoCPreclinical
Initiation of confirmation studies to validate CTL responses to selected viral peptides
EBV-associated lymphomassource ↗
●Patent GrantedIP / Competition
PCT application published for Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models
◆Pipeline PrioritizationCorporate
Planned expansion of TVGN 489 target population to include patients 65+
SARS-CoV-2 infection in patients aged 65 and oldersource ↗
◆Oral PresentationPresentation
CEO to participate in panel at BioNJ's Fifteenth Annual Bio Partnering Conference
▲Platform ValidationPreclinical
Advancement of PredicTcell platform with expanded datasets and wet lab science
▲PublicationPresentation
Proof-of-concept trial results published in Blood Advances
acute viral infections, long-term effects of viral infections, viral and non-viral induced cancerssource ↗
▲Partnership / LicenseCorporate
Collaboration between Tevogen.AI and Microsoft to explore AI applications in biotechnology
▲Safety Data UpdateClinical Data
Positive safety data reported from proof-of-concept clinical trial
▲Patent GrantedIP / Competition
Three granted patents, nine pending US and twelve ex-US pending patents, two related to AI
●FDA Feedback ReceivedFDA Meeting
Met BARDA TechWatch team to discuss ExacTcell technology and TVGN 489
▲Topline ReadoutClinical Data
Positive safety data from proof-of-concept clinical trial for TVGN 489
infectious diseases (COVID-19)source ↗
▲Partnership / LicenseCorporate
Broadened relationship with Microsoft to deepen AI collaboration and develop PredicTcell technology on Azure
Past FDA Catalysts and PDUFA Decisions
How TVGN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F18 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 97%
Micro Cap(rank 638 of 658)
Percentile Rank
Tevogen Bio Holdings Inc. has significant pipeline risk (18/100), with $49M risk-adjusted pipeline value, led by Cytotoxic T Lymphocytes in Covid19 (Phase 1), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytotoxic T Lymphocytes Small moleculeCompletedNCT04765449 | Covid19 | Phase 1 | COMPLETED | 30 | Jan 19, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every TVGN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TVGN 489 | COVID-19 and Long COVID | 2025-10-15 | The dose-finding clinical trial of TVGN 489 demonstrated a favorable safety profile, providing valuable insights for further development, although specific efficacy metrics or outcomes were not disclosed in the press release.Read More | Tevogen Updates on TVGN 489 Following Growing Long COVID Patient InterestRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sordillo Victor J.Director | Grant/Award | 40,000 51,539 held | $0.00 | 07/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TVGN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in TVGN for Q2 2026. | ||||
TVGN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TVGN ranks across every disease it competes in
Competitive Position is a premium feature
See how TVGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTVGN News
-TVGN
Jul 29, 2026▲ +6.3%on this news· ran to +26% by day 3
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
Tevogen Bio Holdings Inc. will officially operate as Tevogen Inc. starting July 30, 2026, following Board approval. This name change signifies the company's transition into a healthcare enterprise focused on integrating biotechnology, artificial intelligence, and healthcare services. The firm aims to enhance the affordability and accessibility of life-saving medicines while continuing to trade under the ticker symbols TVGN and TVGNW.
Read more →-TVGN
Jul 14, 2026Tevogen Bio Announces 2026 Annual Meeting of Stockholders
Tevogen Bio Holdings Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for August 24, 2026. Stockholders of record as of July 23, 2026, will be eligible to vote. Proposals for consideration must be submitted by the same date, adhering to SEC rules and the company's bylaws. Tevogen aims to enhance healthcare accessibility through its various initiatives.
Read more →-TVGN
Jun 9, 2026▼ -7.6%on this news
Tevogen Announces Formation of a Healthcare Services Initiative
Tevogen Bio Holdings Inc. has announced the establishment of a healthcare services initiative led by interim head William Keane. This initiative aims to support the company's evolution into a revenue-generating healthcare enterprise, with potential acquisitions in Management Services Organizations and Contract Research Organizations. The company estimates that these acquisitions could contribute approximately $100 million to its annual revenue, enhancing its commitment to affordable healthcare. Tevogen emphasizes a disciplined approach in evaluating these opportunities to ensure alignment with long-term strategic goals.
Read more →-TVGN
May 28, 2026▲ +11.8%on this news
Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue
Tevogen Bio Holdings Inc. has announced progress in its strategic acquisition initiatives, potentially leading to approximately $100 million in combined annual revenue. The company aims to evolve into a financially self-sufficient healthcare enterprise by exploring acquisitions that complement its existing biotechnology and technology arms. While the initiatives present significant financial potential, they are dependent on due diligence and approvals, and their success is uncertain.
Read more →-TVGN
May 21, 2026▲ +10.4%on this news· ran to -31% by day 3
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
Tevogen Bio Holdings Inc. has signed a Letter of Intent to explore a potential acquisition of a Management Services Organization. This move is aimed at enhancing its healthcare infrastructure and supports the company's evolution into a revenue-generating entity. The CEO expressed that, if successful, the transaction could contribute to an estimated $100 million in annual revenue. However, the completion of the deal is contingent on due diligence, negotiation, and approval processes, which presents inherent uncertainties.
Read more →-TVGN
May 18, 2026▲ +11.3%on this news· ran to +45% by day 3shared move
Letter to Shareholders from CEO Dr. Ryan Saadi
Tevogen Bio Holdings Inc. has reported a significant reduction in operational losses, with a 51% decline from 2024 to 2025. The company is advancing its strategic initiatives, including the Tevogen.AI project and expanding its cell therapy pipeline. CEO Dr. Ryan Saadi emphasized the importance of aligning long-term incentives with performance milestones while maintaining a focus on shareholder equity.
Read more →-TVGN
May 12, 2026Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close
Tevogen Bio Holdings Inc. has announced a $3 million private investment with The Patel Family, LLP, priced at a 14% premium to its latest closing price. This investment aims to enhance Tevogen's operational capabilities, support growth initiatives, and solidify its financial foundation. The financing agreement involves the issuance of 375,000 prefunded warrants, which will close on May 13, 2026. Tevogen's management expressed optimism about the financing's potential benefits in achieving significant revenue milestones.
Read more →-TVGN
Apr 28, 2026▼ -7.3%on this news
Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
Tevogen Bio Holdings Inc. has announced significant advancements in its AI initiative, Tevogen.AI, with the PredicTcell™ training algorithm nearing completion. The model has shown a 10% improvement in precision and the company is exploring partnerships to enhance its application. Additionally, an internal application portal has been developed to streamline workflows and support future commercial efforts.
Read more →-TVGN
Mar 27, 2026▼ -8.3%on this news
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
Tevogen Bio Holdings Inc. is evaluating a niche contract research organization (CRO) to enhance its clinical research capabilities and drive revenue growth. This strategic move could contribute over $20 million annually and support the company's goal of achieving closer to $100 million in revenue. The initiative aligns with Tevogen's mission to provide affordable healthcare solutions in oncology and rare diseases.
Read more →-TVGN
Mar 25, 2026Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement
Tevogen Bio Holdings Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement after facing non-compliance in September 2025. The company aims to transform into a comprehensive healthcare enterprise by combining immunotherapy and artificial intelligence while exploring new strategic initiatives. These initiatives focus on enhancing patient access and affordability while aiming for a cash-flow-positive model. Tevogen's pipeline spans several therapeutic areas, reflecting its commitment to sustainable innovation in healthcare.
Read more →-TVGN
Mar 18, 2026Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
Tevogen Bio Holdings Inc. announced that Mittul Mehta, the Chief Information Officer and Head of Tevogen.AI, will speak at the Microsoft Fabric Community Conference (FabCon 2026) in March 2026. His sessions will focus on the intersection of data engineering and artificial intelligence, addressing modernizing data architecture and building adaptive data pipelines. These themes align with Tevogen.AI's efforts to utilize advanced machine learning to improve biomedical discovery and patient treatment solutions. This participation highlights Tevogen's commitment to integrating cutting-edge technology in healthcare.
Read more →-TVGN
Mar 13, 2026▼ -15.7%on this newsshared move
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure
Tevogen Bio Holdings Inc. has reported advancements in its artificial intelligence platform, Tevogen.AI, specifically in the PredicTcell™ model. The company achieved significant improvements in prediction accuracy, with recall increasing to 92% and precision rising to 48%. Additionally, Tevogen.AI has expanded its proprietary database to over 655 million peptide sequences, enabling more robust model training and target identification. The company plans to explore partnerships to advance its peptide candidates as predictive accuracy continues to improve.
Read more →-TVGN
Mar 13, 2026▼ -15.7%on this newsshared move
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization
Tevogen has provided a strategic update emphasizing its commitment to capital discipline, including the decision to limit share utilization to no more than 1% of its authorized shares in the coming year. The lead investor has expressed strong confidence in Tevogen's growth potential and proprietary technology. Additionally, the company is evaluating acquisitions that could generate over $50 million in annual revenue and is considering a one-time special cash dividend based on future financial milestones. Tevogen's approach reflects a dedication to long-term value creation and operational efficiency.
Read more →-TVGN
Mar 11, 2026Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform
Tevogen, led by CEO Dr. Ryan Saadi, has reiterated its commitment to clinical development during International Long COVID Awareness Month. The company is advancing its investigational T-cell therapy, TVGN 489, and evaluating the acquisition of the Sciometrix Clinicus platform for real-world monitoring of Long COVID patients. Recent proof-of-concept results show that all treated high-risk patients did not develop Long COVID. With plans to expand its HLA target coverage, Tevogen aims to enhance accessibility for a larger portion of the U.S. population.
Read more →-TVGN
Mar 9, 2026▲ +6%on this newsshared move
Tevogen Names Leadership Team to Execute Diversified Growth Strategy
Tevogen Bio Holdings Inc. has appointed interim leaders across its core business sectors to implement a diversified growth strategy. This strategy aims to explore opportunities that could generate over $50 million in annual revenues, with expected closures by Q2 2026. The company is leveraging advanced technologies in healthcare, including AI and precision T cell therapies, to enhance its offerings.
Read more →-TVGN
Mar 5, 2026▼ -16.7%on this newsshared move
Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical
Tevogen Bio Holdings Inc. has signed a non-binding letter of intent to evaluate the potential acquisition of Apozeal Pharmaceutical, aimed at enhancing Tevogen's generics strategy. This transaction could provide Tevogen with an established platform that includes multiple FDA-approved generic drugs and new products in development, supporting its goal of improving pharmaceutical affordability in the U.S. However, the deal is contingent on due diligence, negotiation, and other conditions, with no assurance it will be finalized. Additionally, Tevogen is considering other life sciences-related transactions, although potential challenges remain.
Read more →-TVGN
Mar 4, 2026▼ -24.8%on this news· ran to -37% by day 3shared move
Tevogen Announces Reverse Stock Split
Tevogen Bio Holdings Inc. has announced a reverse stock split of 50-for-1 to comply with Nasdaq's minimum bid price requirement. The split, approved by stockholders, will take effect on March 6, 2026, and will not affect stockholders' ownership percentages, except for fractional shares. The company continues to focus on its innovative healthcare initiatives.
Read more →-TVGN
Feb 26, 2026Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
Tevogen Bio Holdings Inc. has signed a non-binding Letter of Intent to evaluate a potential acquisition of Sciometrix Inc., a healthcare technology provider. This transaction aims to enhance Tevogen's capabilities and establish it as a revenue-generating healthcare enterprise. The deal is subject to due diligence and other customary conditions, with no assurance of completion.
Read more →About Tevogen Bio Holdings Inc.
Headquarters15 INDEPENDENCE BOULEVARD, SUITE #210, WARREN, NJ, 07059
BIOPHARMAWATCH ELITE PLUS
Trade the next TVGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime